Exploring Challenges and Opportunities for Improving Phase 2 and Phase 3 Clinical Trials: A Review

View at publisher Summarise with VIRAT
Authors: Bureddi Anudeep Venkata Sai, Sangita S Mishra, Madhugiri Prakash Venkatesh
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Clinical trials are indispensable for advancing drug discovery, yet Phase 2 and Phase 3 studies are frequently hampered by escalating costs, high attrition rates, and complex operational hurdles. This review will examine current issues, specifically those related to cost, safety, efficacy, and operational inefficiencies. It also analyses the importance of novel approaches like decentralized trials, adaptive designs, digital endpoints, predictive biomarkers, and Artificial Intelligence/ Machine Learning (AI/ML) to improve trial efficiency, participant recruitment, data quality, and overall success rates in drug development. METHODS: A mixed-method strategy was adopted to study the various aspects and challenges of clinical trial designs, including adaptive trial designs, decentralized trials, trial programs by regulatory authorities, and the use of AI/ML models that evaluate large datasets to improve enrollment, enhance design strategies, and forecast outcomes. RESULTS: Although there are still issues with data integrity, adoption of DCTs, adaptive trials, and digital endpoints has increased enrolment, speed, and precision in drug development. Studies are now more effective because of AI/ML-based optimization of recruitment, trial designs, and outcome predictions. DISCUSSION: The findings reveal that while transformative opportunities are emerging, their full potential hinges on overcoming persistent challenges related to standardization, regulatory alignment, ethical considerations, and the digital divide. CONCLUSION: While challenges remain, innovative trial approaches enhance trial efficiency, reduce costs, and improve the likelihood of successful drug development. Multi-faceted strategies are needed to foster a more agile, patient-centric, and ethically sound clinical trial ecosystem, emphasizing the synergistic benefits of integrated technological and methodological advancements.

Fields of Study & Subjects

Statistical Methods in Clinical Trials Ethics in Clinical Research Pharmaceutical studies and practices

Publication details

Journal / source
Reviews on Recent Clinical Trials
Volume
21
Publication date
17 March 2026
Language
EN